Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group

被引：0
|
作者：
C. I. Müller
K. Schulmann
A. Reinacher-Schick
N. Andre
D. Arnold
A. Tannapfel
H. Arkenau
S. A. Hahn
S. H.-J. Schmoll
R. Porschen
W. Schmiegel
U. Graeven
机构：
[1] University Hospital Essen,Institute of Physiology
[2] Ruhr-University of Bochum,Medical Department
[3] Martin Luther University,Medical Department IV, University Clinic
[4] Ruhr-University of Bochum,Institute of Pathology, University Clinic Bergmannsheil
[5] Royal Marsden Hospital and Institute of Cancer Research,Drug Development Unit
[6] Ruhr-University of Bochum,Center for Clinical Research (ZKF, Molecular GI
[7] Medical Department Klinikum Bremen-Ost,Oncology (MGO))
[8] Ruhr-University of Bochum,Division of Gastroenterology and Hepatology, University Hospital Bergmannsheil
[9] Kliniken Maria Hilf GmbH Klinik für Hämatologie,undefined
[10] Onkologie,undefined
[11] Gastroenterologie,undefined
来源：
International Journal of Colorectal Disease | 2008年 / 23卷
关键词：
Colorectal cancer; Microsatellite instability; Chemotherapy; Prognosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1033 / 1039
页数：6
相关论文
共 50 条
  • [21] Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients
    Bécouarn, Y
    Ychou, M
    Ducreux, M
    Borel, C
    Bertheault-Cvitkovic, F
    Seitz, JF
    Nasca, S
    Nguyen, TD
    Paillot, B
    Raoul, JL
    Duffour, J
    Fandi, A
    Dupont-André, G
    Rougier, P
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) : 2739 - 2744
  • [22] Preliminary results from a study of sevacizumab in Chinese patients with metastatic colorectal cancer resistant to oxaliplatin-based first-line chemotherapy.
    Xu, Nong
    Cao, Junning
    Zhang, Yanqiao
    Ding, Yanhua
    Mao, Chenyu
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [23] Relationship between microsatellite instability, response and survival in palliative patients with colorectal cancer undergoing first-line chemotherapy
    Brueckl, WM
    Moesch, C
    Brabletz, T
    Koebnick, C
    Riedel, C
    Jung, A
    Merkel, S
    Schaber, S
    Boxberger, F
    Kirchner, T
    Hohenberger, W
    Hahn, EG
    Wein, A
    ANTICANCER RESEARCH, 2003, 23 (2C) : 1773 - 1777
  • [24] A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer
    Gelibter, Alain J.
    Gamucci, Teresa
    Pollera, Camillo F.
    Di Costanzo, Francesco
    Nuzzo, Carmen
    Gabriele, Angela
    Signorelli, Carlo
    Gasperoni, Silvia
    Ferraresi, Virginia
    Giannarelli, Diana
    Cognetti, Francesco
    Zeuli, Massimo
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (09) : 2117 - 2123
  • [25] Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer
    Zeuli, M
    Nardoni, C
    Pino, MS
    Gamucci, T
    Gabriele, A
    Ferraresi, V
    Giannarelli, D
    Cognetti, F
    ANNALS OF ONCOLOGY, 2003, 14 (09) : 1378 - 1382
  • [26] Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer
    J Feliu
    J M Vicent
    C García-Girón
    M Constela
    E Fonseca
    J Aparicio
    M Lomas
    L Antón-Aparicio
    F J Dorta
    M González-Barón
    British Journal of Cancer, 2004, 91 : 1758 - 1762
  • [27] Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer
    Feliu, J
    Vicent, JM
    García-Girón, C
    Constela, M
    Fonseca, E
    Aparicio, J
    Lomas, M
    Antón-Aparicio, L
    Dorta, FJ
    González-Barón, M
    BRITISH JOURNAL OF CANCER, 2004, 91 (10) : 1758 - 1762
  • [28] Japanese cohort study of first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC) containing fluorouracil, oxaliplatin, and bevacizumab: EMERaLD study, first report
    Taku, Keisei
    Ohata, Kou
    Amano, Toraji
    Ohashi, Yasuo
    Yamazaki, Kentaro
    Watanabe, Masaya
    Satou, Shinsuke
    Ooshima, Takeshi
    Nishikawa, Go
    Hirano, Hidekazu
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [29] Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy
    Ruzzo, Annamaria
    Graziano, Francesco
    Loupakis, Fotios
    Rulli, Eliana
    Canestrari, Emanuele
    Santini, Daniele
    Catalano, Vincenzo
    Ficarelli, Rita
    Maltese, Paolo
    Bisonni, Renato
    Masi, Gianluca
    Schiavon, Gaia
    Giordani, Paolo
    Giustini, Lucio
    Falcone, Alfredo
    Tonini, Giuseppe
    Silva, Rosarita
    Mattioli, Rodolfo
    Floriani, Irene
    Magnani, Mauro
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (10) : 1247 - 1254
  • [30] Oxaliplatin,Fluorouracil and Leucovorin (FOLFOX) as First-line Chemotherapy for Metastatic or Recurrent Colorectal Cancer Patients
    Bing Han Ruihua Xu Yanxia Shi Huiyan Luo Xiaojuan Xiang Yuhong Li Li Zhang Tongyu Lin Youjian HeDepartment of Medical Oncology
    Chinese Journal of Clinical Oncology, 2007, (06) : 397 - 400
12345